Sexual dysfunction in women with multiple sclerosis (MS) is an important yet often overlooked problem. The primary objective of this study is to investigate the prevalence of sexual dysfunction in female patients diagnosed with MS. The secondary objective is to evaluate the relationship between sexual dysfunction and fatigue, depression, anxiety, overactive bladder symptoms, and cognitive dysfunction.
For this purpose, the following validated instruments will be used: the Female Sexual Function Index (FSFI) to assess sexual dysfunction, the Brief International Cognitive Assessment for MS (BICAMS) to evaluate cognitive function, the Hospital Anxiety and Depression Scale (HADS) to assess depression and anxiety, the Fatigue Severity Scale (FSS) to measure fatigue, and the Overactive Bladder Questionnaire (OAB-V8) to evaluate overactive bladder symptoms.
Eligibility
Sex
FEMALE
Min age
25 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria:
* Female patients aged 25-50 years
* Literate and able to comprehend written and spoken instructions
* Diagnosed with relapsing-remitting form of multiple sclerosis
* Having a continuous/regular sexual partner
* Expanded Disability Status Scale (EDSS) score ≤ 5
* At least 3 months since the last relapse
* Sexually active within the past 3 months
* Spasticity level \< grade 2 according to the Modified Ashworth Scale
Exclusion Criteria:
* Pregnancy
* Illiteracy or inability to understand spoken or written instructions
* Absence of a continuous/regular sexual partner
* Expanded Disability Status Scale (EDSS) score \> 5
* Not sexually active within the past 3 months
* Spasticity level ≥ grade 2 according to the Modified Ashworth Scale
Primary outcome measure(s)
Prevalence of sexual dysfunction in female patients with multiple sclerosis — At enrollment (Baseline, cross-sectional assessment)
Trial sites (1)
Facility
City
Region
Status
Ege University Faculty of Medicine, Department of Neurology
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
